Triple A schreef op 22 december 2021 09:14:
[...]
De termijn van 10 jaar gaat pas lopen bij de eerste verkoop en geldt per land. Stel dat de eerste verkoop in de V.S. in januari 2023 is dan loopt die termijn dus af in januari 2033. En stel dat in Frankrijk de eerste commerciële verkoop pas in 2025 is, dan loopt die termijn dus af in 2035.
Verder moet ik zeggen dat ik het niet heel eenvoudig vind om precies te begrijpen wat hier nou staat:
The agreement will terminate on a licensed product-by-licensed product and country-by-country basis upon the expiration of the royalty term for such licensed product in such country, and will terminate in its entirety upon the expiration of the royalty term with respect to the last licensed product then being developed, manufactured or commercialized in all countries of the territory. The royalty term ends on the last to occur of (i) the expiration of the last to expire valid claim of the licensed patents that covers such licensed product in such country; (ii) the expiration of any regulatory exclusivity for such licensed product in such country; or (iii) the ten (10) year anniversary of the first commercial sale of the licensed product in such country. Either party may terminate the agreement upon a material breach by the other party that is not cured within a specified period after receiving written notice. We have the right to terminate the agreement for any reason upon specified prior written notice to Novartis.Met name dat
"on a licensed product by product basis" (komen er dan meer producten?) en dat
"the last to occur" vind ik lastig.